|
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease |
Dretzke J, Edliln R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Dretzke J, Edliln R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technology Assessment 2011; 15(6): 1-250 Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Anti-Inflammatory Agents /adverse effects /economics /therapeutic use; Antibodies, Monoclonal /adverse effects /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Antirheumatic Agents /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; Crohn Disease /drug therapy /economics /pathology; Decision Support Techniques; Great Britain; Humans; Infliximab; Models, Economic; Quality-Adjusted Life Years; Treatment Outcome; Tumor Necrosis Factor-alpha /antagonists & inhibitors AccessionNumber 22011000394 Date bibliographic record published 15/06/2011 |
|
|
|